Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial

Chang Chen, Jianying Huang, Zhenshun Cheng, Jianyuan Wu, Song Chen, Yongxi Zhang, Bo Chen, Mengxin Lu, Yongwen Luo, Jingyi Zhang, Ping Yin, Xinghuan Wang
doi: https://doi.org/10.1101/2020.03.17.20037432

Article usage

Article usage: March 2020 to September 2024

AbstractFullPdf
Mar 202050871015950
Apr 202053489021541
May 20201810908768
Jun 2020626805611
Jul 2020426603597
Aug 2020346502423
Sep 2020325002177
Oct 2020275701879
Nov 2020265191745
Dec 20202587431187
Jan 2021297070901
Feb 2021233231754
Mar 2021258665866
Apr 2021246049875
May 2021232743890
Jun 2021199030540
Jul 2021213135567
Aug 2021159057675
Sep 2021130819512
Oct 2021202420721
Nov 2021144315469
Dec 202191027327
Jan 2022130929362
Feb 2022105031256
Mar 2022104717239
Apr 202280940191
May 202295628180
Jun 202258831178
Jul 202249023147
Aug 202246630133
Sep 202254934115
Oct 20224798130
Nov 20225299125
Dec 202256814143
Jan 202347325149
Feb 202335020100
Mar 20233596130
Apr 20232619124
May 2023198495
Jun 2023204970
Jul 2023170771
Aug 20231941978
Sep 20233422269
Oct 20234861284
Nov 20236383272
Dec 202326215105
Jan 20242541068
Feb 2024300684
Mar 20243488101
Apr 20243101682
May 20243421871
Jun 20243702471
Jul 20244341073
Aug 20245394778
Sep 2024123736
Back to top
Posted March 27, 2020.
Download PDF

Supplementary Material

Data/Code
Email
Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial
Chang Chen, Jianying Huang, Zhenshun Cheng, Jianyuan Wu, Song Chen, Yongxi Zhang, Bo Chen, Mengxin Lu, Yongwen Luo, Jingyi Zhang, Ping Yin, Xinghuan Wang
medRxiv 2020.03.17.20037432; doi: https://doi.org/10.1101/2020.03.17.20037432
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area